STREXIT 2 Project

Learn more about clinical studies in cancer research, the role of real-world evidence in Strexit 2, and the purpose of the international collaboration in this multi-national European project. https://lnkd.in/dBNF3XEP STREXIT 2 is funded by the European Union and is under the legal sponsorship of EORTC - European Organisation for Research and Treatment of Cancer. #STREXIT2_Horizon #HorizonEurope #EUCancerMission #sarcoma #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma European Commission Fondazione IRCCS Istituto Nazionale dei Tumori di Milano The Netherlands Cancer Institute Sarcoma Patient Advocacy Global Network (SPAGN) Syreon Research Institute EORTC - European Organisation for Research and Treatment of Cancer © The STREXIT2 Consortium 2023-2028. This project has received funding from the European Union’s HORIZON-MISS-CANCER-2022-01 under grant agreement Nº (101103843).

The STREXIT2 Project at the #ISPOR2024 Conference Researchers from the Syreon Research Institute presented the STREXIT2 Project at the ISPOR—ISPOR—The Professional Society for Health Economics and Outcomes Research for Health Economics and Outcomes Research Conference in Barcelona. The presentation—"Economic Evaluations and Health Economic Models of Soft Tissue Sarcomas: Systematic Literature Review From a European and North American Perspective"—highlighted important new insights into the health-economic aspects of the project. While a number of publications are available on the economic evaluation of soft tissue sarcomas, they mostly focus on a narrow patient sub-group that is not eligible for surgery. STREXIT2, however, complements the ongoing STRASS2 trial, which investigates the added value of neoadjuvant chemotherapy before surgery for high-risk retroperitoneal sarcoma. Additionally, it includes an observational arm to capture real-world data from patients not participating in STRASS2. Find the whole presentation here: https://lnkd.in/dwx_cJsK #Barcelona #ISPOR #ISPOR2024 #HealthEconomics European Commission EORTC - European Organisation for Research and Treatment of Cancer #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma

We are happy to announce that the third newsletter of the STREXIT 2 Project will be available soon. You can sign up here to receive up-to-date information about the project: https://lnkd.in/dHbFRpPK STREXIT 2 Project is funded by the European Unionnd is under the legal sponsorship of EORTC - European Organisation for Research and Treatment of Cancer. #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma European Commission

Dr Lotte Heimans – Young Investigator of the STREXIT 2 Project Dr Lotte Heimans is an medical oncologist at the Antoni van Leeuwenhoek -The Netherlands Cancer Institute Cancer Institute. Dr Heimans completed her medical degree at Leiden University in 2010 and successfully defended her Ph.D. thesis, “Treatment of Early Rheumatoid and Undifferentiated Arthritis,” at the institution in 2014. Her extensive research includes numerous publications within diverse aspects of arthritis as well as clinical cancer research. EORTC - European Organisation for Research and Treatment of Cancer. European Commission #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma #SarcomaAwareness #FightSarcoma #Oncology #Rheumatology #CancerResearch #ResearchExcellence

The Strexit 2 Project was represented at the meeting of the Horizon Europe Cancer Mission's ‘Diagnosis and Treatment’ cluster. STREXIT2 is one of the 12 EU-funded projects focusing on refractory cancers in the Diagnostics & Treatment Cluster that is part of the European Union Mission on Cancer. On the 12th of September, participants from all cluster members gathered in Barcelona to share insights about their respective projects. Discussions at the event revolved around citizen engagement, addressing inequalities and working on common deliverables. It was a highly forward-looking, inspiring, and productive day, with dedicated professionals from across Europe. Syreon Research Institute AIRC - Foundation for Cancer Research NGO IFOM Hospital del Mar Charité - Universitätsmedizin Berlin Vall d'Hebron Institute of Oncology (VHIO) Digestive Cancers Europe IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Srl Örebro University ICBAS- Abel Salazar Institute of Biomedical Sciences Sagittarius EU Project Care 1 DE-ESCALATE Project Impact-AML IMPORTANT EU Project INTRE-ALL2020 LEGATO Project Liveration PragmaTIL PRIME-ROSE SALVOVAR European Commission EORTC - European Organisation for Research and Treatment of Cancer #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma

  The 17th of September is World Patient Safety Day.  World Patient Safety Day, marked by the World Health Organization, is designed to improve patient safety by highlighting the necessity of global solidarity and coordinated action from all countries and international partners.  Patients are involved in discussions about all aspects of the Strexit 2 trial, from communication to study design.   STREXIT 2 Project is funded by the European Union and is under the legal sponsorship of EORTC - European Organisation for Research and Treatment of Cancer. Find out more about the project here: https://lnkd.in/eQuVVVyA Watch the project's introductory video here: https://lnkd.in/dQmWeaau European Commission #WorldPatientSafetyDay #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma  

Dr Dario Callegaro – Young Investigator of the STREXIT 2 Project Dr Dario Callegaro is a surgical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano in Milan. He completed his university and general surgery residency training in Milan before undertaking a Surgical Oncology fellowship at the University of Toronto from 2018 to 2020. His practice is entirely dedicated to caring for patients with soft tissue sarcoma and gastrointestinal stromal tumors. Since 2017, he has been part of the Sarcoma Service at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, one of Europe's leading centers for sarcoma referrals. His primary research focus revolves around developing and implementing prognostic models for patients with soft tissue sarcomas of the extremity and retroperitoneum. He is the author and co-author of several scientific publications in national and international journals, and in 2015, he was awarded the prestigious VIII Lorini Prize for researchers in the oncology field. EORTC - European Organisation for Research and Treatment of Cancer. European Commission #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma #SarcomaAwareness #FightSarcoma

Dr Dario Callegaro – Young Investigator of the STREXIT 2 Project Dr Dario Callegaro is a surgical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano in Milan. He completed his university and general surgery residency training in Milan before undertaking a Surgical Oncology fellowship at the University of Toronto from 2018 to 2020. His practice is entirely dedicated to caring for patients with soft tissue sarcoma and gastrointestinal stromal tumors. Since 2017, he has been part of the Sarcoma Service at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, one of Europe's leading centers for sarcoma referrals. His primary research focus revolves around developing and implementing prognostic models for patients with soft tissue sarcomas of the extremity and retroperitoneum. He is the author and co-author of several scientific publications in national and international journals, and in 2015, he was awarded the prestigious VIII Lorini Prize for researchers in the oncology field. EORTC - European Organisation for Research and Treatment of Cancer. European Commission #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma #SarcomaAwareness #FightSarcoma

Sarcoma Awareness Month: Interview with Roger Wilson    In observance of Sarcoma Awareness Month, we are honoured to share an insightful interview with Roger Wilson, a sarcoma patient and the founder of Sarcoma UK. Roger also serves as the Honorary President and is an active Board member of the Sarcoma Patient Advocacy Global Network (SPAGN). In this interview, Roger speaks about his years of dedication to patient advocacy, the vital need for early and accurate diagnosis, and the STREXIT 2 Project. His experiences and insights provide a deeper understanding of the challenges and progress in sarcoma diagnosis and care.      Read or listen to the full interview here:  https://lnkd.in/d58SrRHv     STREXIT 2 is funded by the European Union and is under the legal sponsorship of EORTC - European Organisation for Research and Treatment of Cancer.    #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma European Commission Sarcoma Patient Advocacy Global Network (SPAGN) #SarcomaAwareness #FightSarcoma #EarlyDiagnosisSavesLives #sarcomaawarenessmonth2024     

July is Sarcoma Awareness Month Sarcomas are rare cancers that develop in the bones and soft tissues. Due to their rarity, they often receive limited public recognition. However, it is essential to increase awareness about these cancers and to support those affected, including patients, their families, friends, and caregivers. Sarcoma Patient Advocacy Global Network (SPAGN), the global network of national sarcoma support groups emphasizes the importance of early and accurate diagnosis of sarcomas, as it increases the chances of a cure or improved survival.  This July, they have launched a campaign to support this endeavour, along with a survey for patients and caregivers to learn about their pathway to diagnosis. Please find the survey here: https://lnkd.in/dd64cmQD   Learn more about early and correct diagnosis of sarcomas here: https://lnkd.in/dJyTJSap #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma European Commission EORTC - European Organisation for Research and Treatment of Cancer Sarcoma Patient Advocacy Global Network (SPAGN) #SarcomaAwareness #FightSarcoma #EarlyDiagnosisSavesLives #sarcomaawarenessmonth2024